Trial · NCT00710554
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Mean Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale (NRS) Score at the End of Treatment (15 Weeks) | Day 7 to Day 98 | The efficacy analyses were conducted on data from all subjects who were randomised, received at least one dose of study medication and yielded on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in Neuropathic Pain Scale Score at the End of Treatment (15 Weeks) | Day 7 to Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in Sleep Quality 0-10 Numerical Rating Scale Scores at the End of Treatment (15 Weeks) | Day 7 to Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Change in Baseline Mean Dynamic Allodynia Test Score at the End of Treatment (15 Weeks) | Day 7 and Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Change in Baseline Mean Punctate Allodynia Test Scores at the End of Treatment (15 Weeks) | Day 7 and Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Subject Global Impression of Change | Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | participants | NUMBER |
| SECONDARY | Change From Baseline in Brief Pain Inventory (Short Form) Scores at the End of Treatment | Day 7 and Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in Quality of Life EuroQol 5-D (Health Status Index) Score at the End of Treatment (15 Weeks) | Day 7 and Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in Quality of Life EuroQol 5-D (Health Status Visual Analogue Scale) Score at the End of Treatment (15 Weeks) | Day 7 and Day 98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in the Use of Rescue Analgesia at the End Treatment (15 Weeks) | Days 0-7 and Days 92-98 | The primary population for the analysis of efficacy was the full analysis set, which included all randomised subjects who received at least one dose of test treatment and had on-treatment efficacy data. | number of tablets | MEAN |
| SECONDARY | Incidence of Adverse Events as a Measure of Subject's Safety. | 19 weeks | All subjects were included in this analysis. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00710554/outcomes